Data Provided by Refinitiv. Minimum 15 minutes delayed.

MannKind to Sponsor Andretti Autosport Type 1 Diabetes Driver, Conor Daly

IndyCar Driver Living with Diabetes Helps Raise Awareness for Diabetes Treatment Options

WESTLAKE VILLAGE, Calif., March 14, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) announced today it is sponsoring Conor Daly as he makes his debut with the Andretti Autosport team at the 103rd Running of the Indianapolis 500 on May 26, 2019. MannKind is an associate sponsor of Andretti Autosport for this race and will partner with Daly on his No. 25 U.S. Air Force Honda. Daly was diagnosed with Type 1 diabetes at the age of 14, and now lends his racing career to raise awareness of diabetes treatment options and innovations.

“Living with diabetes since age 14 has been a challenge, but one that I’ve always faced head on,” said Daly. “Managing my diabetes properly has been a key to being able to live my racing dream.  Diabetes should never stop you from pursuing what you want in life!  Thanks to MannKind I will be able to share my story and live my dream at a higher level than ever."

“MannKind is continually seeking platforms to increase awareness around the challenges, opportunities and successes people living with diabetes encounter on a daily basis,” says Michael Castagna, CEO of MannKind. “Seeing someone like Conor take on a challenging sport such as IndyCar racing, while having to manage his diabetes, is an inspiration to all those living with diabetes. We are excited to be associated with Conor and Andretti Autosport for the Indy 500 and look forward to a partnership where we can help educate people on treatment options for managing their diabetes.”

As an associate sponsor of Daly at the Indy 500, MannKind is planning events and experiences that build awareness of innovation in diabetes treatment.  The events and sponsorship promotion will also allow for Daly to share his story about living with diabetes.

About MannKind Corporation
MannKind Corporation (NASDAQ:MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company's first FDA-approved product and the only inhaled rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing and research facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S. For further information, visit

About Andretti Autosport
Led by racing legend Michael Andretti, Andretti Autosport boasts a wide racing portfolio rooted in tradition and designed for success.

Under the banners of Andretti Autosport, Andretti Rallycross and Andretti Formula E, the Indianapolis-based team fields multiple entries across the IndyCar Series, Indy Lights, the FIA Formula E Championship, the GT4 America Series and Americas Rallycross. Additionally, the team competes as Walkinshaw Andretti United in the Australian Supercars category through partnership with Walkinshaw Racing and United Autosports.

The global racing enterprise boasts four IndyCar Series championships, three Indy Lights titles, one Pro Mazda championship and one USF2000 championship, and has captured victory five times at the famed Indianapolis 500-Mile Race. Additionally, the team holds two X Games Gold Medals and four U.S. rallycross championships.

To share in the Andretti story, please visit online at and follow along on social media with #AllAndretti.

Company Contact:
Rose Alinaya
SVP, Investor Relations


Source: MannKind

Data Provided by Refinitiv. Minimum 15 minutes delayed.